Daily
250 words
5/10
Rating

18 July 2026

CDSCO approval for Wegovy for fatty liver disease

The approval of a new drug by the CDSCO is a significant development in public health policy and medical regulation, providing useful context for questions regarding healthcare infrastructure and pharmaceutical governance in India.

1 min read Day 2 of 3 1 questions 1 prelims

Notes

  • The Central Drugs Standard Control Organization (CDSCO) has approved Wegovy (semaglutide injection 2.4 mg) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH).
  • Wegovy is the first and only GLP-1 receptor agonist (GLP-1 RA) approved in India for this specific indication.
  • The approval is intended for adults with moderate to advanced liver fibrosis.
  • The treatment is indicated for use in conjunction with a reduced-calorie diet and increased physical activity.
  • MASH is characterized by excess fat buildup in the liver, leading to chronic inflammation and liver damage.

Part of a longer story

This is day 2 of 3 in Semaglutide market developments in India, which has been running since 16 July 2026. Reading it whole is usually worth more than reading today alone — the exam asks how something developed.

Questions

  1. Discuss the role of the Central Drugs Standard Control Organization (CDSCO) in regulating new drug indications in India. How does the approval of novel therapies for metabolic disorders reflect the evolving landscape of public health management in the country? 150 words
    Attempt this — 150 words in 8 min
    0 / 150 words 8:00

Prelims

  1. The drug 'Wegovy' (semaglutide), recently approved by the CDSCO for treating MASH, belongs to which class of medications?

Syllabus

Topics

Sources

250words.in · https://250words.in/daily/2026-07-18/cdsco-approval-for-wegovy-for-fatty-liver-disease